- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03238196
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives
To determine the safety and tolerability of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.
Secondary Objectives
- To determine the anti-tumor effect of fulvestrant, palbociclib and erdafitinib in patients with ER+/HER2-/FGFR-amplified MBC.
- Pharmacokinetic assessments of erdafitinib
Correlative Objectives
- To determine the therapeutic predictive role of FGFR1-4, CCND1-2, CDK4 and CDK6 amplifications, and RB1 and ESR1 mutations on clinical outcome
- To determine if the FGFR1 amplification levels is an early surrogate of response
- To determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to CDK4/6 and FGFR inhibition
- To determine pharmacodynamic biomarkers of FGFR inhibition
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Baptist Memorial Hospital Memphis
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75235
- University of Texas Southwestern Simmons Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be able to swallow and retain oral medication
- Patients must be ≥ 18 years of age
- Female patients of no childbearing potential must be post-menopausal. Postmenopausal female subjects should be defined prior to protocol enrollment by any of the following:
- Participants at least 60 years of age; OR
- Participants under 60 years of age and naturally (spontaneous, no alternative pathologic or physiological cause) amenorrhea for at least 12 months; OR
- Medical ovarian failure confirmed by follicle-stimulating hormone (FSH) and estradiol levels in the post menopausal range per local institutional normal range; OR
- Prior bilateral oophorectomy; OR
- Prior radiation castration with amenorrhea for at least 6 months; OR
- Treatment with a luteinizing hormone-releasing hormone (LH-RH) agonist (such as goserelin acetate or leuprolide acetate) is permitted for induction of ovarian suppression as long as it has been initiated at least 28 days prior to study enrollment
- Patients must have ECOG performance status 0 - 1
- Patients must have clinical stage IV or inoperable locoregional recurrent invasive mammary carcinoma that is:
- ER+ and/or PgR+ (≥ 1% positive stained cells) by immunohistochemistry (IHC)
- HER2-negative (by IHC or FISH, per ASCO guidelines)
- FGFR1 - 4 amplified
- Patients must have evaluable (may have either measurable or non-measurable) disease
- Patients must have available tissue for FGFR determination
- Patients must have had at least one line of therapy in the metastatic setting
- Current use of any of the drugs listed on the Cautionary Concomitant Med list has to be approved by the Study Chair
- Patients must have adequate hematologic, hepatic and renal function. All laboratory tests must be obtained within 2 weeks from study drug initiation. These include:
- ANC ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- HgB ≥ 9.0 g/dL
- Creatinine clearance ≥ 40 mL/min/1.73 m2
- SGOT, SGPT ≤ 2.5 x ULN if no liver metastasis present; SGOT, SGPT ≤ 4 x ULN if liver metastasis present
- Albumin ≥ 2.0 g/dL
- Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN if known Gilbert's syndrome)
- Potassium within institutional normal limits
- Phosphorus ≤ institutional upper limit of normal
Exclusion Criteria:
- Prior use of an FGFR inhibitor
- More than 2 lines of chemotherapy in the metastatic setting. No limit on endocrine therapy lines. Prior exposure to CDK4/6 inhibitor acceptable.
- Radiation therapy ≤ 2 weeks prior to study entry. Patients who have received prior radiotherapy must have recovered from toxicity (≤ grade 1) induced by this treatment (except for alopecia)
- Prior cancer therapy (except for endocrine therapy) must have been discontinued for 1 week prior to initiation of study drugs
- Concurrent anti-cancer therapy other than the ones specified in the protocol is not permitted during study participation. Bisphosphonates or denosumab are allowed
- Major surgery within 4 weeks of enrollment
- Herbal preparations are not allowed throughout the study, and should be discontinued 14 days prior to initiation of study treatment
- Any corneal or retinal abnormality likely to increase the risk of eye toxicity, such as:
- Current corneal pathology such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
- Uncontrolled glaucoma despite standard of care therapy
- Diabetic retinopathy with macular edema
- Known active wet, age-related macular degeneration (AMD)
- Known central serous retinopathy (CSR) or retinal vascular occlusion (RVO)
- Uncontrolled intercurrent illness including, but not limited to:
- Malabsorption syndrome significantly affecting gastrointestinal function
- Ongoing or active infection requiring antibiotics/antivirals
- Impairment of lung function (COPD > grade 2, lung conditions requiring oxygen therapy)
- Symptomatic congestive heart failure
- Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
- Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [National Cancer Institute -Common Terminology Criteria for Adverse Events, Version 4.03, grade 3]
- QTcF ≥ 480 msec on screening EKG
- Known history of clinically significant QT/QTc prolongation or Torsades de Pointes(TdP)
- ST depression or elevation of ≥ 1.5 mm in 2 or more leads
- Diarrhea of any cause ≥ CTCAE grade 2 that does not resolve within a few days when adequately treated with anti-diarrhea medications
- Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary
- Symptomatic brain metastases (patients with a history of brain metastases must be clinically stable for more than 4 weeks from completion of radiation treatment and be off steroids)
- Known history of chronic liver or chronic renal failure
- Poor wound healing capacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Escalation
Fulvestrant - injection into muscle 1 time per month Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken) Erdafitinib tablet taken by mouth 1 time per day |
4mg - 8mg
Other Names:
125 mg
Other Names:
500 mg
Other Names:
|
Experimental: Expansion
Fulvestrant - injection into muscle 1 time per month Palbociclib capsule taken by mouth 1 time per day every 21 days followed by 1 week of rest (no drug taken) Erdafitinib tablet taken by mouth 1 time per day |
4mg - 8mg
Other Names:
125 mg
Other Names:
500 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
Time Frame: From the time of randomization up to 4 weeks of treatment (cycle 1), for each patient
|
Number of participants with DLT in the first cycle for the determination of the MTD.
|
From the time of randomization up to 4 weeks of treatment (cycle 1), for each patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Tolerability]
Time Frame: From date of randomization until 28 days post treatment discontinuation from any cause, assessed up to 48 months
|
Assessment of adverse events throughout the study
|
From date of randomization until 28 days post treatment discontinuation from any cause, assessed up to 48 months
|
Progression-free Survival
Time Frame: Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
|
Assessment of clinical impact [anti-tumor effect] of the combination of erdafitinib, palbociclib and fulvestrant in patients with ER+/ FGFR amplified metastatic breast cancer will be assessed by measuring the interval (in months) between treatment initiation and disease progression.
|
Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
|
Overall Response Rate
Time Frame: Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
|
Assessment of clinical impact [anti-tumor effect] of the combination of erdafitinib, palbociclib and fulvestrant in patients with ER+/ FGFR amplified metastatic breast cancer by measure the rate (%) of complete and partial responses seen in patients with measurable disease
|
Imaging studies will be performed every 8 weeks from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
|
Clinical Benefit Rate (CBR; Complete Response + Partial Response + Stable Disease Without Disease Progression at 6 Months)
Time Frame: From the time of randomization up to 6 months for each patient
|
Assessment of clinical impact [anti-tumor effect] of the combination of erdafitinib, palbociclib and fulvestrant in patients with ER+/ FGFR amplified metastatic breast cancer by measure the rate (%) of complete and partial responses + stability of disease at 6 months seen in patients with measurable disease
|
From the time of randomization up to 6 months for each patient
|
Pharmacokinetic Assessment of Erdafitinib - Area Under the Curve (AUC)
Time Frame: From the time of randomization up to 4 weeks of treatment for each patient
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration
|
From the time of randomization up to 4 weeks of treatment for each patient
|
Pharmacokinetic Assessment of Erdafitinib - Cmax (Maximum Plasma Concentration)
Time Frame: From the time of randomization up to 4 weeks of treatment for each patient
|
The maximum (peak) observed plasma drug concentration after oral dose administration
|
From the time of randomization up to 4 weeks of treatment for each patient
|
Pharmacokinetic Assessment of Erdafitinib - Tmax
Time Frame: From the time of randomization up to 4 weeks of treatment for each patient
|
Time to reach maximum (Cmax) plasma drug concentration after oral dose administration (time)
|
From the time of randomization up to 4 weeks of treatment for each patient
|
Pharmacokinetic Assessment of Erdafitinib - CL/F
Time Frame: From the time of randomization up to 4 weeks of treatment for each patient
|
Apparent total body clearance of drug from the plasma after oral administration
|
From the time of randomization up to 4 weeks of treatment for each patient
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Next Generation Sequencing
Time Frame: At study entry (baseline)
|
Will determine if other genomic alterations other than FGFR amplifications correlate with clinical outcome.
|
At study entry (baseline)
|
Serial Measurements of Serum Phosphate, Calcium, Vitamin D, Parathyroid Hormone (PTH), FGF23, sFGFR2, sFGFR3, and sFGFR4
Time Frame: During the first 8 weeks of treatment (days 1, 8, 15, 22 of cycle 1 and days 1 and 15 of cycle 2)
|
Serial measurements of serum phosphate, calcium, vitamin D, PTH), FGF23, sFGFR2, sFGFR3, and sFGFR4 will be assessed to detect on target effects of FGFR inhibition (pharmacodynamic assessments).
|
During the first 8 weeks of treatment (days 1, 8, 15, 22 of cycle 1 and days 1 and 15 of cycle 2)
|
FGFR1 Amplification Levels by FISH and cfDNA
Time Frame: At study entry (baseline)
|
The level of FGFR1 amplification assessed in tumors by fluorescence in situ hybridization (FISH) will be correlated with clinical outcome.
|
At study entry (baseline)
|
Plasma Cell-free Deoxyribonucleic Acid (cfDNA)
Time Frame: At study entry (baseline), at 4 weeks, and at study discontinuation from disease progression (for each patient), assessed up to 48 months.
|
Will determine if the cfDNA results at disease progression show new genomic alterations potentially associated with resistance to CDK4/6 and FGFR inhibition.
|
At study entry (baseline), at 4 weeks, and at study discontinuation from disease progression (for each patient), assessed up to 48 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Brent Rexer, MD, PhD, Vanderbilt-Ingram Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protein Kinase Inhibitors
- Hormone Antagonists
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Palbociclib
Other Study ID Numbers
- VICC BRE 16126
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Erdafitinib
-
Memorial Sloan Kettering Cancer CenterRecruitingBladder Cancer | Recurrent Bladder Cancer | FGFR3 Gene MutationUnited States
-
Janssen Research & Development, LLCTerminatedHepatic ImpairmentGermany
-
Janssen Research & Development, LLCCelerionCompleted
-
Janssen Research & Development, LLCActive, not recruitingAdvanced Solid TumorFrance, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Poland, Taiwan, China, Italy, Spain, Australia, Brazil, Argentina
-
Janssen Pharmaceutical K.K.Completed
-
Janssen Scientific Affairs, LLCApproved for marketingAdvanced Cancers and FGFR Genetic Alterations
-
M.D. Anderson Cancer CenterActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...United States
-
Lung Cancer Group CologneTerminatedNSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary NeoplasmGermany
-
University Health Network, TorontoCompletedOvarian Cancer | Steroid Cell Tumor, MalignantCanada
-
Janssen Research & Development, LLCCompletedNeoplasmChina, Taiwan, Korea, Republic of